Cardiol Therapeutics (TSE:CRDL) Rating Reiterated by HC Wainwright

Cardiol Therapeutics (TSE:CRDL)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research note issued on Monday, BayStreet.CA reports.

Cardiol Therapeutics Stock Performance

Shares of TSE:CRDL opened at C$2.49 on Monday. The company’s 50 day simple moving average is C$2.28 and its 200 day simple moving average is C$1.61. The stock has a market capitalization of C$162.12 million, a price-to-earnings ratio of -5.79 and a beta of 0.75. The company has a debt-to-equity ratio of 0.52, a current ratio of 5.29 and a quick ratio of 6.84. Cardiol Therapeutics has a 1 year low of C$0.74 and a 1 year high of C$2.94.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19, as well as for the treatment of recurrent pericarditis and acute myocarditis.